Guerbet

2019 Revenue

2019 revenue

Activity growth consistent with the objectives:

+3.5% at current exchange rates and +2.0% at constant exchange rates

Villepinte, 13 February 2020 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting 2019 revenue of €816.9 million, up 3.5% from 2018, including a favourable forex impact of €11.3 million. Revenue was up 2.0% at €805.6 million at constant exchange rates¹. Fourth quarter 2019 revenue was €211.2 million, up 1.4% at constant exchange rates.

Excluding the impact of the decrease related to the subcontracting activities inherited from the CMDS activities, revenue growth at constant exchange rates was 3.7% over the 2019 financial year and 3.1% in fourth quarter 2019.

Consolidated Group revenue (IFRS)

In millions of euros, at 31 December 2019	Change (%)	2019 at current exchange rates	Change (%)	2019 at constant exchange rates*	Reported 2018
Sales in Europe	+1.7%	345.2	+1.9%	346.0	339.5
Sales in Other Markets	+4.8%	471.7	+2.1%	459.6	450.1
Total	+3.5%	816.9	+2.0%	805.6	789.6

 

Growth in all regions

In Europe, growth was around 2% at constant exchange rates despite slight pressure on Dotarem prices in Belgium and Switzerland. 

Excluding the impact of the subcontracting activities inherited from the CMDS activities, sales grew in the Americas by 3% at constant exchange rates thanks to market shares increase, in the MRI segment, particularly in North America.

In Asia, the group’s growth was strong at 10.3% at constant exchange rates with the switch to direct distribution in Japan and good performance in other countries.

The analysis of activity over the 2019 financial year shows that:

• Diagnostic Imaging sales grew to €711.0 million at constant exchange rates (+3.0%) and €719.5 million at current exchange rates.

Sales in the MRI² segment totalled €271.4 million at constant exchange rates and like-for-like basis (€275.0 million at current exchange rates) compared with sales of €272.0 million in 2018. In 2019, activity suffered from the planned withdrawal of Optimark from the market. Excluding Optimark, MRI sales at constant exchange rates were up 1.6%.